Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations
Semaglutide is a glucagon-like peptide-1 receptor agonist that slows gastric emptying, which can affect how your body absorbs oral medicationsincluding antibiotics
This represents one of the highest success rates ever documented for any single intervention in MCAS treatment
However, evidence on longer-term effects and side effects remains limited or uncertain, partly due to potential conflicts of interest
Regarding macrovascular complications, comparable incidence of myocardial infarction was observed between patients receiving SGLT2i and GLP1-RA, which was consistent with a population-based cohort study [37]
Yerba mate's caffeine content can temporarily increase heart rate and energy expenditure, though the effect diminishes with regular consumption due to caffeine tolerance
